Site Search
Displaying results 381 - 390 of 573
Resource | Publications,
WHO, with support from Centers for Disease Control and Prevention (CDC), developed the present tool on specifications and quantities for efficient procurement of essential equipment and laboratory commodities for HIV.
The ultimate purpose of the tool is to facilitate the efficient procurement of laboratory equipment and laboratory commodities required to:
- perform HIV diagnostic tests in adults, adolescent and children;
- monitor treatment outcomes in patients on antiretroviral therapy.
Resource | Publications,
PA-824 belongs to the nitroimidazoles class of compounds and is a derivative of compound CGI-17341 whose anti-TB activity was reported as early as 1993. PA-824 was discovered by Patho- Genesis Corporation, which was subsequently acquired by Chiron Corporation. Novartis AG acquired Chiron Corporation in 2006. PA-824 is a pro-drug, which requires reductive activation of an aromatic nitro group before it becomes effective against TB bacteria.
Resource | Publications,
Sutezolid belongs to the oxazolidinone class of compounds, which function as protein synthesis inhibitors and were first discovered in the mid-1980s. Linezolid was the first compound of the oxazolidinone class to be approved for treatment of TB. It is most commonly used to treat drug-resistant TB. However, linezolid’s use has been limited by toxicity concerns, particularly haematological effects after periods of treatment over 14 days.
Given the potential of sutezolid, this report explores the patent landscape and considers possible access issues relating to the drug should it become available on the market.
Resource | Publications,
TB treatment has become more complex, particularly with the emergence of multidrug-resistant (MDR) strains of Mycobacterium tuberculosis. There were approximately 450 000 new cases of multidrug-resistant tuberculosis (MDR-TB) worldwide in 2012.1 MDR-TB is resistant to the two most commonly used TB drugs, isoniazid and rifampicin. It requires extended treatment with second-line drugs that are less effective and have more adverse effects than isoniazid- and rifampicin-based regimens.
Given the emergence of MDR-TB, and the need to shorten treatment duration, new drugs are required. The last of the current anti-TB treatments—rifampicin—was introduced in 1963. Since then, research for new TB treatments had largely come to halt. However, in recent years the pipeline for potential new TB treatments has started to look more promising than it has for the past 50 years.
One compound that is currently in the pipeline and generating interest is AstraZeneca's investigational compound AZD5847. AZD5847 has been identified as a possible new treatment for drug-susceptible TB and/or for MDR-TB.
Resource | Publications,
Delamanid was discovered via a screening programme carried out by Otsuka. The compound belongs to the nitroimidazole class of compounds and is a derivative of compound CGI-17341 whose anti-TB activity was already reported in 1993. Previously known as OPC-67683, delamanid is a mycolic-acid biosynthesis inhibitor found to be free of mutagenicity and to possess highly potent activity against tuberculosis (TB), including multidrug-resistant-tuberculosis (MDR-TB).
Resource | Publications,
This report provides evidence of raised expectations translated into figures and a ‘calling-to-account’ of the key players in the national response to AIDS. There is a rising expectation on the Nauru's government, not only to honour the commitment to the Political Declaration on AIDS endorsed in 2011 but also to ensure that the interventions set out to reach the commitments are successful, constructive and accountable. Common objectives such as reaching ‘Universal Access to Prevention, Care and Treatment’ and the Political Declaration of 2011 helped realize that HIV is one of the world’s challenges which is too interconnected and complex for any country to handle. These challenges further consolidate the need for greater collaboration between government and civil society.
Resource | Guidelines,
This document provides guidance to countries for assessing the utility of data from programmes for prevention of mother-to-child transmission (PMTCT) of human immunodeficiency virus (HIV) for HIV sentinel surveillance (HSS) among pregnant women.
This guidance document is written for national HIV/acquired immunodeficiency syndrome (AIDS) programme managers, surveillance officers and epidemiologists responsible for monitoring HIV trends in low- and middle-income countries.
Resource | Publications,
This report summarises the results of qualitative research that was conducted to better understand reasons for initiating, continuing and ceasing treatment among PLHIV in the Pacific Islands. In total, 49 PLHIV were inter-viewed, including 23 HIV-positive people in Fiji, 11 HIV-positive people in Guam, 2 HIV-positive people in Kiribati, 5 HIV-positive people in Samoa and 8 HIV-positive people in Solomon Islands. A training workshop was held in November 2011 where the team of 10 PLHIV peer researchers, 2 training support facilitators and the team leader worked in collaboration to develop the method for the study. In-depth interviews were selected as the research method to gain a detailed understanding of the participants’ treatment experiences. Research participants were recruited through PLHIV support networks where they exist and through health clinics that provide treatment to PLHIV.
Resource | Publications,
The purpose of this report is to highlight new developments and key challenges that UNITAID has faced as an organization and donor during 2012. This report will be the last to follow the Board approved key performance indicators (KPIs) set for the UNITAID Strategy 2010-2012. The report summarizes UNITAID’s results measured against the targets for 2012 set by its Executive Board at the beginning of the Strategy cycle for 2010-2012.
The report summarizes UNITAID's results measured against the targets for 2012 set by its Executive Board at the beginning of the Strategy cycle for 2010-2012.
Resource | Publications,
UNITAID’s Strategy 2013-2016 guides the organization’s response to HIV/AIDS, malaria and TB. In total, these global epidemics kill almost 4 million people every year. Forward looking and flexible, UNITAID collects intelligence on product markets for these diseases in order to inform its investments, which are implemented by the world’s top development organizations.